DEF: Zomedica Corp. Announces Annual Meeting of Shareholders: Director Elections and Executive Compensation on the Agenda

Zomedica Corp. will hold its Annual Meeting of Shareholders on June 10, 2025, to vote on director elections, auditor ratification, and executive compensation.

Summary

• Zomedica Corp. is holding its Annual Meeting of Shareholders on June 10, 2025, virtually.
• Shareholders will vote on electing eight director nominees, ratifying the appointment of Grant Thornton LLP as the independent registered public accounting firm for 2025, and providing an advisory vote on executive compensation.
• The record date for determining shareholders eligible to vote is April 21, 2025.
• The Board of Directors recommends voting FOR the election of director nominees, FOR the ratification of Grant Thornton LLP, and FOR the approval of executive compensation.
• As of the record date, there were 979,949,668 outstanding Common Shares.
• The Board met six times in 2024.
• The annual compensation for each outside director is $50,000 per year, payable in quarterly installments, commencing in 2023.
• The Chairman of the Board receives an additional $10,000 in annual compensation, and each committee chair receives an additional $5,000 in annual compensation, payable in quarterly installments.

Sentiment

Score: 7

Explanation: The document is primarily informational, outlining the agenda and procedures for the annual meeting. The tone is professional and neutral, with a focus on corporate governance and shareholder engagement.

Positives

• The Board is composed of a majority of independent directors.
• The company has adopted a Code of Ethics applicable to all officers, directors, and employees.
• The company has adopted insider trading policies and procedures.
• The company has adopted a Clawback Policy which provides for the recovery of certain incentive compensation in the event of an accounting restatement.

Negatives

• At the 2024 annual meeting, only 46% of shares were cast in favor of the compensation of our named executive officers, 51.3% of shares were cast against our executive compensation and 2.6% of shares abstained from the say on pay vote.

Risks

• Failure to ratify the appointment of Grant Thornton LLP as the independent registered public accounting firm could necessitate finding a replacement.
• Negative shareholder feedback on executive compensation could lead to changes in compensation policies.
• Cybersecurity risks are overseen by the Audit Committee, but breaches could still occur.

Future Outlook

The Board intends to consider the results of the advisory vote on executive compensation when making future compensation decisions.

Management Comments

• The Board believes that the Company's compensation program for executive officers is designed to attract and retain high-quality people and to motivate them to achieve both our long-term and short-term goals.
• Our executive compensation program is intended to attract, motivate, reward and retain the senior management talent required to achieve our corporate objectives and increase shareholder value.
• Our philosophy in setting compensation policies for executive officers is to align pay with performance, while at the same time provide competitive compensation.

Industry Context

This announcement is a standard part of corporate governance, ensuring shareholders have a voice in key decisions like director elections and executive compensation, which is common across publicly traded companies.

Comparison to Industry Standards

• The director compensation structure, with base pay and additional compensation for committee chairs, is typical among publicly traded companies.
• The use of Grant Thornton LLP as an independent auditor is a common practice to ensure financial transparency and compliance.
• Holding an advisory vote on executive compensation (say-on-pay) is a standard practice mandated by the Dodd-Frank Act, aligning with practices at companies like Zoetis, Elanco, and Heska prior to its acquisition.

Management Changes

Corporate Governance

Related Party Transactions

• Other than compensation arrangements for our named executive officers and directors, there was no transaction or series of transactions, since January 1, 2023 to which we were a party or will be a party, in which: the amounts involved exceeded or will exceed US $120,000; and any of our directors, executive officers or holders of more than 5% of our Common Shares, or any member of the immediate family of the foregoing persons (related persons), had or will have a direct or indirect material interest.

Stakeholder Impact

• Shareholders have the opportunity to vote on key decisions affecting the company.
• Employees are subject to the Code of Ethics and insider trading policies.
• Executive officers' compensation is subject to shareholder advisory vote.

Next Steps

• Shareholders should review the proxy materials and vote on the proposals.
• The Company will hold the Annual Meeting on June 10, 2025.
• The Board and Compensation Committee will consider the results of the advisory vote on executive compensation.

Key Dates

Keywords

Annual Meeting, Shareholders, Proxy Statement, Director Election, Executive Compensation, Grant Thornton, Corporate Governance, Zomedica